Efficient amyloid-β degradation in Alzheimer’s disease using SPYTACs
Cell · 2026-04 · 189 (7) · 1923-1941.e26
DOI: 10.1016/j.cell.2026.01.034 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell, 2026-04. Verfasst von Fei Teng und 14 weiteren Autor:innen. Beteiligte Einrichtung: Medical School, University of Chinese Academy of Sciences, Beijing 100049, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, Lysosomes, Peptides. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Chinese Academy of Sciences.
Themen: Demenz
Abstract (Originalsprache)
Clearance of aberrant cerebral amyloid-β (Aβ) deposits represents a promising therapeutic strategy for Alzheimer's disease (AD), yet current anti-Aβ immunotherapy raises safety concerns due to frequent adverse effects. Extracellular targeted protein degradation (eTPD) offers an approach for safe and efficient clearance of disease-causing proteins. Here, we develop a next-generation eTPD platform, synthetic peptide-programmed lysosome-targeting chimeras (SPYTACs), using entirely synthesized bispecific peptides. Leveraging low-density lipoprotein receptor-related protein 1 (LRP1), SPYTACs effectively facilitate targeted degradation of extracellular proteins and enable transcytosis across the blood-brain barrier. In vivo administration of SPYTACs effectively reduces peripheral and cerebral Aβ burden, attenuates synapse loss, and improves cognitive function in 5×FAD mice at both prodromal and symptomatic stages. Notably, SPYTAC treatment shows fewer side effects, including intracerebral hemorrhage and inflammation, compared with conventional immunotherapies. The high modularity and genetic encodability enable SPYTACs to target customized disease-causing proteins, underscoring their therapeutic versatility and translational promise across diverse diseases driven by pathogenic proteins.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical School, University of Chinese Academy of Sciences, Beijing 100049, China.
- State Key Laboratory of Organ Regeneration and Reconstruction, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China.
- Medical School, University of Chinese Academy of Sciences, Beijing 100049, China; State Key Laboratory of Organ Regeneration and Reconstruction, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China.
- Medical School, University of Chinese Academy of Sciences, Beijing 100049, China; State Key Laboratory of Organ Regeneration and Reconstruction, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China;…
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Chinese Academy of Sciences
- Canadian Anesthesiologists' Society
Zitieren
APA
Teng, F., Liu, J., Cui, T., Tan, X., Liu, K., Hou, Z., Zhou, L., Xie, Y., Li, R., Li, D., Li, B., Wang, D., Zhou, Q., Hu, B., & Li, W. (2026). Efficient amyloid-β degradation in Alzheimer’s disease using SPYTACs. Cell, 189(7), 1923-1941.e26. https://doi.org/10.1016/j.cell.2026.01.034
Vancouver
Teng F, Liu J, Cui T, Tan X, Liu K, Hou Z, et al. Efficient amyloid-β degradation in Alzheimer’s disease using SPYTACs. Cell. 2026;189(7):1923-1941.e26. doi:10.1016/j.cell.2026.01.034
BibTeX
@article{Teng2026,
author = {Teng, Fei and Liu, Jing and Cui, Tongtong and Tan, Xiangtian and Liu, Kailun and Hou, Zongren and Zhou, Li and Xie, Yuanzhi and Li, Rongqi and Li, Da and Li, Bojin and Wang, Dongmei and Zhou, Qi and Hu, Baoyang and Li, Wei},
title = {Efficient amyloid-β degradation in Alzheimer’s disease using SPYTACs},
journal = {Cell},
year = {2026},
volume = {189},
number = {7},
pages = {1923--1941.e26},
doi = {10.1016/j.cell.2026.01.034}
}
EUVIMED